The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. In an ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...
The research uncovers a previously unappreciated mechanism by which macrophages influence the fate of CFs post-MI. It demonstrates that macrophage-derived IFN-β stimulates the IFN-β-IFNAR-p-STAT1 axis ...
Type 1 diabetes confers a cardiovascular burden that is often obscured by the young age of affected individuals and by the ...
A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
Scientists at Northwestern University and at the University of California San Diego have developed a potent injectable therapy that the results of rodent studies showed can protect the heart from ...
Objective: To determine whether changes in health maintenanceorganization (HMO) penetration or payer mix affected inhospitalmortality and treatment patterns of patients with acutemyocardial infarction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results